Kyntra Bio receives Nasdaq delisting determination; requests hearing to remain listed

KYNTRA BIO, INC.

Nasdaq Staff determined on Sept 30, 2026 to delist Kyntra Bio (KYNB) after it missed the Sept 29, 2026 deadline to comply with Listing Rule 5450(b).
Kyntra requested a Nasdaq Hearings Panel review, which stays suspension and Form 25-NSE filing; KYNB continues trading on Nasdaq Global Select Market.
Company previously got Nasdaq notice on April 2, 2026 for failing Rule 5450(b)(3)(A), which requires at least $50 million in total assets and total revenue.
An extension period could run up to 180 days from the Staff delisting Determination under Listing Rule 5815(c)(1)(A), but no assurance of relief is given.
Kyntra Bio is preparing a compliance plan for the Panel; General Counsel John Alden signed on October 6, 2026.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.